Advertisement

Advertisement

2016 ASH Annual Meeting

Advertisement

Advertisement



Jan
22
Today In Oncology
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Using T-Cell Fraction to Predict Melanoma Recurrence
irAEs and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma
Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
View More 
Advertisement
Most Read Stories
Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
Management of HER2-Positive Breast Cancer: Business as Usual?
Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC
View More 
Most Viewed Videos
Catherine M. Diefenbach, MD, on Follicular Lymphoma: Polatuzumab Vedotin Plus Obinutuzumab/Lenalidomide
Belinda Kingston, MB ChB, on the Genomic Landscape of Breast Cancer Based on ctDNA Analysis
Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab
Javier Cortes, MD, PhD, on Triple-Negative Breast Cancer: Results From the KEYNOTE-119 Trial of Pembrolizumab vs Chemotherapy
Nicoletta Colombo, MD, on Lenvatinib/Pembrolizumab for Advanced Endometrial Cancer
View More 
© 2020 HSP News Service, L.L.C.